Powered by Google Google ÜbersetzerGoogle Übersetzer
Latest Press Releases
View all
TimeHeadline
1m agoWesBanco Announces First Quarter 2026 Financial Results
2m agoBioMarin Announces Board Leadership Transition
2m agoNHI Announces Sale of NHC Portfolio for $560 Million
2m agoZscaler Wins 2026 Google Cloud Partner of the Year Award for Security in the Application Category
2m agoARMOUR Residential REIT, Inc. Announces May 2026 Dividend Rate Per Common Share
Biomarin Pharmaceutical Inc logo

Biomarin Pharmaceutical Inc

About

Biomarin Pharmaceutical Inc (NASDAQ:BMRN) — investor relations, events, news, and company updates on 6ix.

Latest News

Today
BioMarin Announces Board Leadership Transition
Mar 13 2026
Roctavian (BioMarin Pharmaceutical) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
Mar 12 2026
BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
Mar 12 2026
BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Geneti...
Feb 27 2026
U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)

Financials

Revenue
$3.22 B
Market Cap
$10.67 B
P/E Ratio
30.83
EPS
1.80

Community Chat

Ask AI

6ix6ix
Originaltext
Diese Übersetzung bewerten
Mit deinem Feedback können wir Google Übersetzer weiter verbessern